BR112017021114A8 - Compostos heterocíclicos como inibidores de lsd1 - Google Patents

Compostos heterocíclicos como inibidores de lsd1

Info

Publication number
BR112017021114A8
BR112017021114A8 BR112017021114A BR112017021114A BR112017021114A8 BR 112017021114 A8 BR112017021114 A8 BR 112017021114A8 BR 112017021114 A BR112017021114 A BR 112017021114A BR 112017021114 A BR112017021114 A BR 112017021114A BR 112017021114 A8 BR112017021114 A8 BR 112017021114A8
Authority
BR
Brazil
Prior art keywords
heterocyclic compounds
lsd1 inhibitors
lsd1
compounds
inhibitors
Prior art date
Application number
BR112017021114A
Other languages
English (en)
Other versions
BR112017021114B1 (pt
BR112017021114A2 (pt
Inventor
He Chunhong
Li Zhenwu
Wu Liangxing
Yao Wenqing
Zhang Fenglei
Original Assignee
Incyte Corp
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp, Incyte Holdings Corp filed Critical Incyte Corp
Publication of BR112017021114A2 publication Critical patent/BR112017021114A2/pt
Publication of BR112017021114A8 publication Critical patent/BR112017021114A8/pt
Publication of BR112017021114B1 publication Critical patent/BR112017021114B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

COMPOSTOS HETEROCÍCLICOS COMO INIBIDORES DE LSD1, SEU USO, COMPOSIÇÃO FARMACÊUTICA QUE OS COMPREENDE E MÉTODO PARA INIBIR A DEMETILASE LISINA-ESPECÍFICA 1 (LSD1) IN VITRO. A presente invenção refere-se aos compostos da Fórmula I que são inibidores da LSD1 úteis no tratamento de doenças, tais como o câncer.
BR112017021114-9A 2015-04-03 2016-04-01 Compostos heterocíclicos como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método para inibir a demetilase lisina-específica 1 (lsd1) in vitro BR112017021114B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562142717P 2015-04-03 2015-04-03
US62/142,717 2015-04-03
US201562183906P 2015-06-24 2015-06-24
US62/183,906 2015-06-24
PCT/US2016/025550 WO2016161282A1 (en) 2015-04-03 2016-04-01 Heterocyclic compounds as lsd1 inhibitors

Publications (3)

Publication Number Publication Date
BR112017021114A2 BR112017021114A2 (pt) 2018-07-03
BR112017021114A8 true BR112017021114A8 (pt) 2023-01-24
BR112017021114B1 BR112017021114B1 (pt) 2023-07-18

Family

ID=

Also Published As

Publication number Publication date
AU2016243939B2 (en) 2020-09-03
MY191796A (en) 2022-07-15
EP3626720A1 (en) 2020-03-25
CR20170500A (es) 2018-02-02
ZA201706710B (en) 2022-05-25
CL2017002483A1 (es) 2018-03-16
CN107660205B (zh) 2021-08-27
IL254736A0 (en) 2017-11-30
US11401272B2 (en) 2022-08-02
US9944647B2 (en) 2018-04-17
JP6995623B2 (ja) 2022-01-14
US20200392143A1 (en) 2020-12-17
JP2018510193A (ja) 2018-04-12
CN107660205A (zh) 2018-02-02
US20160289238A1 (en) 2016-10-06
US20190055250A1 (en) 2019-02-21
KR20180003552A (ko) 2018-01-09
ECSP17073191A (es) 2018-03-31
WO2016161282A1 (en) 2016-10-06
TW201713660A (zh) 2017-04-16
CO2017011216A2 (es) 2018-03-20
MA51438A (fr) 2021-04-14
ES2757948T3 (es) 2020-04-30
MX2017012699A (es) 2018-02-09
AU2016243939A1 (en) 2017-10-26
UA122688C2 (uk) 2020-12-28
TWI714567B (zh) 2021-01-01
IL254736B (en) 2022-01-01
EA201792205A1 (ru) 2018-02-28
PH12017501817A1 (en) 2018-04-23
CA2981661A1 (en) 2016-10-06
US10800779B2 (en) 2020-10-13
HK1249905A1 (zh) 2018-11-16
SG11201708047UA (en) 2017-10-30
CA2981661C (en) 2023-10-03
EP3277689B1 (en) 2019-09-04
PE20180455A1 (es) 2018-03-05
EP3277689A1 (en) 2018-02-07
BR112017021114A2 (pt) 2018-07-03

Similar Documents

Publication Publication Date Title
CO2017011851A2 (es) Compuestos novedosos
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
CO2017011484A2 (es) Inhibidores de bromodominio
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112017012342A2 (pt) compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
BR112015032595A2 (pt) inibidores de ido
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
BR112016025396A2 (pt) derivados de heterociclil-butanamida
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
BR112016001645A8 (pt) derivados de oxoquinazolinil-butanamida, seu uso, medicamentos e kit

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: INCYTE HOLDINGS CORPORATION (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/04/2016, OBSERVADAS AS CONDICOES LEGAIS